Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Sarepta

Why IBD Stock Of The Day Sarepta Just Snagged A Price Target Hike Over Pfizer

IBD Stock Of The Day Sarepta will lead the gene therapy market in treating a form of muscular dystrophy, an analyst said Monday.

Investors Business Daily

Dow Jones Futures Fall: Market Rally At Pivotal Point; Tesla, Enphase Skid

Dow Jones Futures Fall: Market Rally At Pivotal Point; Tesla, Enphase Skid

The stock market rally showed resilience, as the Dow Jones slashed early losses, but is at a pivotal point. Tesla fell while Enphase plunged.

Investors Business Daily

Best Stocks In The IBD 50 Can Be Found By Using This Simple Tool

Best Stocks In The IBD 50 Can Be Found By Using This Simple Tool

Sarepta Therapeutics and Albemarle are among several companies in the IBD 50 whose stocks are above their 10-week lines.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Something Unusual Is Happening Right Now With Biotech Stocks

Biotech stocks have swung sharply higher, buoyed by several factors. Could they be poised to lead the market though the next big upturn?

Investors Business Daily

15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome

In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.

Investors Business Daily

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update

Here's a roundup of top developments in the biotech space over the last 24 hours:

inkl

Read news from The Economist, FT, and more,
with one subscription

IBD 50 Stocks To Buy And Watch: Gene Therapy Leader Gains On New Data, Potential FDA Approval

IBD 50 Stocks To Buy And Watch: Gene Therapy Leader Gains On New Data, Potential FDA Approval

Sarepta is building a base as this biotech stock tries to convince regulators to approve its gene therapy.

Investors Business Daily

Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study

Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular dystrophy.

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership

Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to

People

Joseph Schwartz

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

European Commission

Investor Business Daily

Arista Networks

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

262,940 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play